

Venous Thromboembolism (VTE)




Pr **innohep**[®]
tinzaparin sodium

Conveniently available in multiple dosage formats*



Prevention of postoperative VTE...3 colour coded prefilled syringes available

Prevention of postoperative VTE in orthopaedic surgery

Recommended dose and dosage adjustment*






Prefilled syringes	Dose per syringe	Pre-operative 50 anti-Xa IU/kg body weight†	Post-operative 75 anti-Xa IU/kg body weight†
	2,500 anti-Xa IU	-	-
	3,500 anti-Xa IU	70 (60–80) kg	45 (35–55) kg
	4,500 anti-Xa IU	90 (80–100) kg	60 (50–70) kg

†Value represents the average weight ± 10 kg appropriate for the syringe size. Patients outside of these weight ranges should be dosed on an individual basis.

Type of Surgery	Recommended dose and dosage adjustment*
Hip Surgery 	50 anti-Xa IU/kg given by SC injection two hours before surgery followed by 50 anti-Xa IU/kg once daily for 7-10 days OR 75 anti-Xa IU/kg, given post-operatively by SC injection once daily for 7-10 days
Knee Surgery 	75 anti-Xa IU/kg, given post-operatively by SC injection once daily for 7-10 days

Treatment of VTE....6 colour coded prefilled syringe sizes to help you discover the closest innohep[®] fit

20,000 anti-Xa IU/mL prefilled syringes for the treatment of DVT/PE

Prefilled syringes	Patient body weight		DVT/PE Recommended dose: 175 anti-Xa IU/kg SC once daily	
	(kg)	(lb)	Dose (IU)	Amount (mL)
 8,000 anti-Xa IU/0.4mL	31 – 36	68 – 80	6,000	0.3
	37 – 42	81 – 94	7,000	0.35
	43 – 48	95 – 107	8,000	0.4
 10,000 anti-Xa IU/0.5mL	49 – 53	108 – 118	9,000	0.45
	54 – 59	119 – 131	10,000	0.5
 12,000 anti-Xa IU/0.6mL	60 – 65	132 – 144	11,000	0.55
	66 – 70	145 – 155	12,000	0.6
 14,000 anti-Xa IU/0.7mL	71 – 76	156 – 168	13,000	0.65
	77 – 82	169 – 181	14,000	0.7
 16,000 anti-Xa IU/0.8mL	83 – 88	182 – 194	15,000	0.75
	89 – 93	195 – 205	16,000	0.8
 18,000 anti-Xa IU/0.9mL	94 – 99	206 – 218	17,000	0.85
	100 – 105	219 – 231	18,000	0.9

DVT: Deep vein thrombosis; PE: Pulmonary embolism; SC: Subcutaneous

The recommended maximum daily dose for innohep[®] is 18,000 anti-Xa IU/day. Concomitant treatment with oral anticoagulants is usually started immediately. Treatment with innohep[®] should be continued until therapeutic oral anticoagulant effect has been achieved (INR 2.0 to 3.0), usually within 5 days. The average duration of innohep[®] treatment is 7 days.

Published clinical data are available documenting extended treatment with innohep[®] 175 IU/kg once daily for 3–6 months in patients with cancer associated thrombosis. The use of innohep[®] beyond 6 months must be evaluated in the absence of clinical data.¹

All patients with renal impairment treated with LMWHs should be monitored carefully. Consideration of dosage adjustment in patients with severe renal impairment should be undertaken.

* Please consult the Product monograph for complete dosing and administration information

REFERENCES: 1. Current innohep[®] Product Monograph. LEO Pharma Inc.

© 2021 LEO Pharma Inc. innohep[®] and the LEO Lion logo are registered trademarks of LEO Pharma A/S under license and distributed by LEO Pharma Inc. Canada

- Once daily dosing for the treatment of VTE
- Each treatment prefilled syringe is graduated **and has a 29 gauge needle**
- Orange safety shield designed to prevent needle stick injuries



STORAGE AND STABILITY

- Should be stored at room temperature (15 to 25°C)
- Should not be refrigerated



Prinnohep[®] (tinzaparin sodium) is indicated for:¹

- The prevention of postoperative venous thromboembolism in patients undergoing orthopaedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism
- The prevention of clotting in indwelling intravenous lines for haemodialysis and extracorporeal circulation in patients without high bleeding risk
- The treatment of deep vein thrombosis and/or pulmonary embolism

For more information:

Please consult the Product Monograph at www.leo-pharma.ca/innohep_pm for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available through our Medical Information department at 1-800-263-4218.

Pr **innohep**[®]
tinzaparin sodium
Discover the potential within